



# Bevacizumab Solution for IV Infusion

## CADTH Formulary Management Expert Committee Responses to Questions From the Drug Programs

**Table 1: Response Summary**

Implementation issue	FMEC response
<b>Considerations for discontinuation of therapy</b>	
Is there evidence to support continuing treatment with single-drug bevacizumab if a patient is unable to tolerate bevacizumab in combination with lomustine?  What is the rationale (if any) to continue on bevacizumab if lomustine is discontinued?	FMEC refers to the discontinuation criteria outlined in Table 2 of the reimbursement recommendation.

FMEC = CADTH Formulary Management Expert Committee.